scholarly journals Comparing weight method and float method for pressurised metered dose inhaler as dose counting method.

2020 ◽  
Author(s):  
Gobi Hariyanayagam Gunasekaran ◽  
Syazwan Faiz b. Kamal Al Arif ◽  
Shargunan Selvanthan Gunasekaran ◽  
Sera Selvanthan Sundram Gunasekaran

Abstract INTRODUCTION Pressurised metered-dose inhalers (pMDIs) are not equipped with dose counters, so estimating the actuation remaining is difficult. We compared weight method and float method in estimating the actuation remaining in discarded pMDIs.METHODOLOGY Used non-metered pMDIs were collected from Pharmacy department Hospital Seri Manjung from June to Dec 2018. Each of the returned canister was evaluated using float and weight method to predict the balance actuation in the canister. For the float test, the canister was placed in a container of water. Based on its position in the water, the pMDI was categorised as 1=empty, 2=¼ full, 3=½ full, 4=¾ full, or 5=full. For the weight method, canisters were weighed, and actuation remaining were calculated using a linear regression equation where the general equation is: Actuation remaining = Constant + β*pMDI weight, and further categorised as above. The percentage of empty pMDIs between the two methods were compared.RESULTS A total of 4517 pMDIs were returned to the pharmacy, of which 2131 (47%) were salbutamol, 1149 (25%) budesonide, 685 (15%) ipratropium/fenoterol, 340 (8%) innovator fluticasone, 182 (4%) generic fluticasone, and 30 (1%) beclomethasone. Overall, the float method classified 75% pMDIs as empty, compared to 71% by the weight method. The percentage of empty salbutamol, generic fluticasone, and beclomethasone pMDIs were similar between both methods. A higher percentage of budesonide pMDIs were classified as empty by the float method compared to the weight method (62% vs 37%). For ipratropium/fenoterol pMDIs, the float method did not identify any empty canisters, but 82% were classified as empty by the weight method. CONCLUSION This study produced a prediction equation that can be used to estimate remaining actuation in a pMDI based on its weight. There were differences in the identification of empty pMDIs between the float test and the weight method, which varied by drug. The weight method may be a convenience method to be used to measure actuation remaining in pMDIs returned to the pharmacy, as well as patients’ adherence to pMDIs.

2020 ◽  
Author(s):  
Gobi Hariyanayagam Gunasekaran ◽  
Syazwan Faiz b. Kamal Al Arif ◽  
Shargunan Selvanthan Gunasekaran ◽  
Sera Selvanthan Sundram Gunasekaran

Abstract INTRODUCTION Pressurised metered-dose inhalers (pMDIs) are not equipped with dose counters hence the balance actuation in a canister could not be determined. Each actuation expels a considerable amount of active ingredients and excipients from a canister, thus the balance actuation remaining in a pMDI based on canister weight could be evaluated using a linear regression equation.METHODOLOGY New pMDIs of 5 active ingredients [salbutamol (GSK) 200 actuation, budesonide (Glenmark) 300 actuation, ipratropium/fenoterol (Boehringer) 200 actuation, fluticasone (GSK/innovator) 120 actuation, fluticasone (Cipla/generic) 120 actuation, and beclometasone (Ivax) 200 actuation] was weighted . using a laboratory scale (Sartorius R200D; 0.01g accuracy). Two of each pMDI were weighed after each actuation, with a 30-second inter-puff interval, and the mean weight was recorded. To minimise variability in measurements, weighing was limited to one operator. The canister was considered empty when there were no changes in weight after repeated actuation. The prediction equation (one for each pMDI) was the line of best fit through data points on the scatter plot of the number of actuations versus weight.RESULTS AND DISCUSSION There was low variability between pMDIs weights (SD: 0.03g-0.08g)] of the same active ingredients indicating manufacturing uniformity among canisters. Prediction equations were generated for each type of active ingredients, where the general equation is: Actuation remaining = Constant + β*pMDI weight.CONCLUSION This study produced a prediction equation that can be used to estimate remaining actuation in a pMDI based on its weight. Weighing medication canister could be used to measure actuation remaining in pMDIs, as well as patients’ adherence to pMDIs.


2013 ◽  
Vol 31 (5) ◽  
pp. 1325-1337 ◽  
Author(s):  
Yang Chen ◽  
Paul M. Young ◽  
David F. Fletcher ◽  
Hak Kim Chan ◽  
Edward Long ◽  
...  

2013 ◽  
Vol 66 (5) ◽  
pp. 639-645 ◽  
Author(s):  
Alessandro Saadat ◽  
Bing Zhu ◽  
Mehra Haghi ◽  
Gregory King ◽  
Gaia Colombo ◽  
...  

Author(s):  
Touraj Ehtezazi

Introduction: Serious COVID-19 respiratory problems start when the virus reaches the alveolar level, where type II cells get infected and die. Therefore, virus inhibition at the alveolar level would help prevent these respiratory complications. Method: A literature search was conducted to collect physicochemical properties of small molecule compounds that could be used for the COVID-19 treatment. Compounds with a low melting point were selected along with those soluble in ethanol, hydrogen-bond donors, and acceptors. Results : There are severe acute respiratory syndrome coronavirus inhibitors with physicochemical properties suitable for the formulation as an ultrafine pressurised metered-dose inhaler (pMDI). Mycophenolic acid, Debio 025, and cyclosporine A are prime candidates among these compounds. Cyclosporine A (hereafter cyclosporine) is a potent SARS-CoV-2 inhibitor, and it has been used for the treatment of COVID-19 patients, demonstrating an improved survival rate. Also, inhalation therapy of nebulised cyclosporine was tolerated, which was used for patients with lung transplants. Finally, cyclosporine has been formulated as a solution ultrafine pMDI. Although vaccine therapy has been started in most countries, inhalation therapies with non-immunological activities could minimise the spread of the disease and be used in vaccine-hesitant individuals. Conclusion: Ultrafine pMDI formulation of cyclosporine or Debio 025 should be investigated for the inhalation therapy of COVID-19.


Sign in / Sign up

Export Citation Format

Share Document